Prosecution Insights
Last updated: November 19, 2026
Application No. 18/838,678

SYNTHESIS OF BRUTON'S TYROSINE KINASE INHIBITORS

Non-Final OA §102
Filed
Aug 15, 2024
Priority
Feb 18, 2022 — GR 20220100151 +3 more
Examiner
KUCHARCZK, JED A
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Janssen Pharmaceutica N.V.
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
6m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
82 granted / 102 resolved
+20.4% vs TC avg
Strong +16% interview lift
Without
With
+16.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
36 currently pending
Career history
144
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
34.5%
-5.5% vs TC avg
§102
19.2%
-20.8% vs TC avg
§112
26.4%
-13.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 102 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statement (IDS) submitted on 11/08/2024 was filed in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Election/Restrictions Applicant’s election without traverse of Group I, claims 55-77 and the compound of claim 68 in the reply filed on 08/12/2026 is acknowledged. Claims 78-80 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention/species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 08/12/2026. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 55-60 and 67-68 are rejected under 35 U.S.C. 102((a)(1)/(a)(2)) as being anticipated by WO2017100662A1 (see 11/08/2024 IDS). The prior art discloses synthesis of Example 298 on pp. 298-299; Intermediate 18 on pp. 115-116; and Intermediate 36 on pp. 123-125. Example 298 is equivalent to applicant’s elected species and is a compound of claim 55 wherein R1 is PNG media_image1.png 71 118 media_image1.png Greyscale and R2 is C2 alkenyl; it is also a compound of Formula (II) of claim 68. The compound produced in Step A in intermediate 36 is equivalent to instantly claimed CMPD-10 of claim 68 which is a species of CMPD-01 of claim 55. Step B of intermediate 36 teaches contacting said compound with methanesulfonic acid in DCM (an acid and a first solvent). Intermediate 18 in the prior art is equivalent to CMPD-11 instantly claimed which is a species of CMPD-02 of claim 55. Example 298 teaches contacting the product of step B with Intermediate 18 in the presence of HATU (a coupling agent), TEA (an amine base), and DMF (a second solvent) to obtain the compound of Example 298 (equivalent to the instantly claimed compound of Formula (II). Accordingly, claims 55-60 and 68 are anticipated. The synthesis of Step A requires reacting the equivalent of instantly claimed CMPD-09 with triethylamine and propenyl chloride to form CMPD-01 wherein Pg is Boc and R2 is C2 alkenyl, thereby anticipating claim 67. Allowable Subject Matter Claims 61-66 and 69-77 objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Claims 55-60 and 67-68 are rejected. Claims 61-66 and 69-77 are objected to. Claims 78-80 are withdrawn. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JED A KUCHARCZK whose telephone number is (571)270-5206. The examiner can normally be reached Mon-Fri 7:30 to 5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan can be reached at (571) 270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JED A KUCHARCZK/Examiner, Art Unit 1623 /ADAM C MILLIGAN/Supervisory Patent Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Aug 15, 2024
Application Filed
Sep 10, 2025
Response after Non-Final Action
Nov 02, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790309
CANNABICHROMENE DERIVATIVES AND METHODS FOR MAKING AND USING THE SAME
2y 10m to grant Granted Nov 10, 2026
Patent 12788745
ANTIVIRAL THERAPY WITH IMIQUIMOD AND COCRYSTALS THEREOF
2y 3m to grant Granted Nov 10, 2026
Patent 12766121
METHOD FOR TREATING AND/OR PREVENTING EPILEPSY AND REDUCING SIDE EFFECT OF ANTI-EPILEPTIC DRUG BY USING CYNARIN
2y 5m to grant Granted Oct 20, 2026
Patent 12753148
Solid Forms, Salts and Polymorphs of Anti-fibrotic Compounds
2y 9m to grant Granted Oct 06, 2026
Patent 12741940
DOPAMINE RECEPTOR D1 AGONISTS AND METHODS OF USE
4y 8m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
97%
With Interview (+16.3%)
2y 9m (~6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 102 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month